Cromos Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Cromos Pharma is a mid-sized, privately-held CRO that has established a strong niche through its geographic focus and innovative commercial models. Its core strategy leverages cost-effective and high-recruiting clinical trial regions in Eastern Europe and Central Asia, supported by US operational leadership. A key differentiator is its 'No Patients – No Payment™' risk-sharing program for patient recruitment, which mitigates sponsor risk. With over 22 years of experience, the company has managed 450+ trials across 70+ indications, enrolling over 150,000 patients.

OncologyRare DiseaseCardiovascular

Technology Platform

Integrated clinical trial service platform combining US operational leadership with deep regional expertise in Central/Eastern Europe & Central Asia. Proprietary tools include a Clinical Trial Budget Calculator, Free Multicountry Feasibility Reports, and the 'No Patients – No Payment™' risk-sharing recruitment program.

Opportunities

Growing demand for cost-effective, fast-patient-recruitment in emerging clinical trial regions like Central and Eastern Europe.

Increased outsourcing by small and mid-sized biotechs, who are particularly attracted to risk-sharing models like 'No Patients – No Payment™'.

Regulatory complexity post-Brexit and under the EU CTR drives need for specialized EU legal representation and strategy services.

Risk Factors

High geographic concentration risk in politically volatile regions like Central and Eastern Europe.

Intense competition from large, global CROs with greater resources.

Dependency on the R&D spending cycles of the biopharmaceutical industry, which can be impacted by economic downturns.

Competitive Landscape

Operates in the highly fragmented and competitive global CRO market. Competes with large, full-service CROs (e.g., IQVIA, ICON, Parexel) on service breadth and with smaller, niche CROs on regional expertise. Its primary competitive differentiation is its hybrid US/emerging market operational model and its unique risk-sharing recruitment program.

More companies in Digital Health & Biotech SaaS →More companies in United States →